Strategic partnerships Opportunity to re-engage with legacy stakeholders and capitalize on prior collaborations, such as the Proximo Medical partnership in US markets, to expand COBRA PzF NCS distribution and support channels in new regions.

Clinical momentum Leverage the Shield trial data and positive first-in-man results to position COBRA PzF as a next-generation nanocoated stent option, targeting cardiovascular centers pursuing innovative coatings and reduced restenosis risk.

Key leadership The appointment of a seasoned medical device CEO signals growth readiness; align client discussions with executive-led strategic initiatives, exploring co-development or broader commercialization agreements and access to capital for scale.

NanoCoating value Highlight Polyzene-F nanocoating’s differentiator as a basis for premium pricing in markets seeking enhanced biocompatibility and device longevity; pursue conversations with hospital systems and distributors prioritizing advanced surface technologies.

Financial positioning With modest revenue and substantial funding, there is room to offer bundled or tiered sales partnerships, including private-label or joint marketing programs, to accelerate market penetration while de-risking larger deployments.